In early trading today, A-Shares rebounded from shock, and the Shanghai stock index made up for the gap of downward jump on Friday. Both Shanghai and Shenzhen 300 and Shanghai Stock Exchange 50 rose by more than 1%.
On the disk, the concept of digital economy is fully active, and the sub sectors such as digital currency, software services, cloud computing and big data have set off a wave of limit trading, while the pharmaceutical sector that was still popular yesterday has made a comprehensive correction, and the sub sectors such as covid-19 detection, covid-19 drug concept, traditional Chinese medicine and gene concept have made a significant correction. The net inflow of funds going north was 3.221 billion yuan
the concept of digital economy is hot
The concept of digital economy has strengthened again today, and relevant stocks in multiple segments have concentrated trading limits.
In early trading, the concept of digital currency continued to open higher in large quantities, and the sector index rose by more than 5%, reaching a record high. The half day transaction exceeded the full day transaction yesterday, Shenzhen Tianyuan Dic Information Technology Co.Ltd(300047) , Synthesis Electronic Technology Co.Ltd(300479) 20% limit, Beijing Advanced Digital Technology Co.Ltd(300541) , Shenzhen Forms Syntron Information Co.Ltd(300468) and other limits or rose by more than 10%; The software service sector also rose by more than 3%, a new high in more than a year, and more than 20 shares such as Surfilter Network Technology Co.Ltd(300311) rose by the limit or more than 10%; Cloud computing and big data sectors also had more than 20 shares trading or more than 10%; State owned cloud, digital twin, smart city, information security and other related sectors all rose sharply.
Since the new year, favorable policies for the digital economy have emerged one after another. Recently, Qiushi magazine published an important article “constantly strengthening, optimizing and expanding China’s digital economy”; The national development and Reform Commission also issued a document “vigorously promoting the healthy development of China’s digital economy”, proposing to concentrate on tackling key core technologies and accelerate the realization of high-level self-reliance and self-improvement; Appropriately advance the deployment of new infrastructure construction and consolidate the foundation for the development of digital economy; We will further promote the digital transformation of traditional industries and accelerate the deep integration of digital technology and the real economy. Earlier, the State Council issued the 14th five year plan for the development of digital economy, which made it clear that by 2025, the digital economy will move towards a period of comprehensive expansion, and the added value of the core industries of the digital economy will account for 10% of GDP.
Local governments are also making vigorous efforts to introduce relevant plans. Today, Hua Yuan, Deputy Secretary General of the Shanghai municipal government and director of the municipal development and Reform Commission, said that during the 14th Five Year Plan period, Shanghai will accelerate the construction of a “3 + 6” new industrial system, strive to speed up the layout of new tracks, actively seize the digital economy tracks, and comprehensively promote the digital transformation of the city. In addition, it will also guide enterprises to strengthen research on important platforms for the interaction between the future virtual world and the real society, such as emerging industries such as yuancosmos.
Earlier, the work report of Wuhan municipal government proposed to “accelerate the growth of digital industry”, and the added value of digital economy will account for more than 50% of GDP in the next three years; Dongguan City proposed to make overall arrangements for financial funds of no less than 10 billion yuan in three years to promote industrial digitization and digital industrialization; During the “14th five year plan” period, Suzhou will dynamically invest more than 100 billion yuan of special funds to support the development of industrial innovation clusters in the era of digital economy.
Galaxy Securities believes that in the future, the digital economy will enter a new development cycle from virtual to real. The new digital infrastructure is expected to accelerate its growth, supported by policy dividends. The release of data elements, the improvement of cloud rate and the promotion of industrial Internet application penetration will have relatively clear benefit targets. Key recommendations: Yonyou Network Technology Co.Ltd(600588) , Shanghai Baosight Software Co.Ltd(600845) , Beijing Kingsoft Office Software Inc(688111) , Beijing Tongtech Co.Ltd(300379) , Runa Smart Equipment Co.Ltd(301129) , State Grid Information&Communication Co.Ltd(600131) , Trs Information Technology Co.Ltd(300229) , Servyou Software Group Co.Ltd(603171) .
pharmaceutical stocks suddenly cooled
Pharmaceutical stocks, which were still hot yesterday, suddenly cooled down and fell to the freezing point today. The subdivisional sector covid-19 detection jumped short, opened low and went low. The sector index once fell by nearly 7%, the largest one-day decline since the index was launched, Hangzhou Alltest Biotech Co.Ltd(688606) once fell by 20%, while the previous stock once rose by nearly twice this year, and nearly 20 stocks such as Anxi biology and Hangzhou Biotest Biotech Co.Ltd(688767) fell by the limit or more than 10%; The concept of Helicobacter pylori also fell by nearly 6%, Nanjing Hicin Pharmaceutical Co.Ltd(300584) and other nearly 10 stocks fell by the limit or more than 10%; Covid-19 drug concept, gene concept, anti influenza, traditional Chinese medicine and other sectors all led the decline. The sharp drop in pharmaceutical stocks also led to a sharp correction in related pharmaceutical ETFs. Among the top 10 ETFs that fell today, 7 were only pharmaceutical ETFs.
There are many factors contributing to the sharp rise of pharmaceutical stocks. First, the short-term rise is too large. The short-term highest share prices of Anxi biology, Hangzhou Biotest Biotech Co.Ltd(688767) , Beijing Hotgen Biotech Co.Ltd(688068) and other pharmaceutical stocks all rose more than doubled this year, accumulating huge profits.
Secondly, due to the short-term surge, a number of pharmaceutical companies released risk warning announcements today. Fujian Cosunter Pharmaceutical Co.Ltd(300436) said that the anti covid-19 virus small molecule oral innovative drug project of Zhonglin biology, the holding subsidiary of the company, is still in the preclinical research stage, and the preclinical candidate compound (PCC) needs to be determined through compound property characterization research, so as to complete preclinical pharmaceutical research and pharmacokinetic, pharmacodynamic, pharmacological and toxicological research in line with clinical registration application, Phase I, II and III clinical studies shall be carried out after obtaining the clinical (implied) license of nmpa. After obtaining the corresponding safety and efficacy data, the drug registration application can be submitted to nmpa. After obtaining the drug registration certificate and passing the GMP compliance inspection of API, the project products can be produced and sold. New drug research and development has the characteristics of high risk, high investment and long cycle, which draws the attention of investors to the risk. Hybio Pharmaceutical Co.Ltd(300199) , Staidson(Beijing) Biopharmaceuticals Co.Ltd(300204) , Zhejiang Hisun Pharmaceutical Co.Ltd(600267) , Frontier Biotechnologies Inc(688221) have also expressed similar views.
In addition, recently listed pharmaceutical new shares broke one after another. First, after the first day of listing, Baiji Shenzhou continued to decline. As of noon today, it closed at 133.14 yuan, down more than 30% from the issue price of 192.6 yuan.
Today, Maiwei biology, which has the concept of covid-19 medicine, broke when it was listed again, and the lowest price fell by nearly 29% compared with the issue price. It can be said that it poured a basin of ice water on the speculation of relevant concept stocks, making it cool rapidly.
Maiwei bio is an innovative biopharmaceutical enterprise. Its main business is the R & D, production and sales of therapeutic biological products, specifically antibody drugs including human therapeutic monoclonal antibodies, bispecific / bifunctional antibodies and ADC drugs, as well as long-acting or specially modified cytokine recombinant protein drugs.
According to the prospectus of Maiwei biology, the company has carried out the neutralization activity detection of 9mw3311 against the mutant strains of covid-19 virus originating in the UK, South Africa, Brazil, India and California, and confirmed that 9mw3311 maintained the neutralization activity of the UK mutant, but partially or completely inactivated the mutants in South Africa, Brazil, India and California. This makes Maiwei biology hot before listing, and the market expectation is unprecedented.
According to the closing price of 25.23 yuan at noon today, the market value of Maiwei biology is as high as more than 10 billion yuan. However, the latest financial data show that its operating revenue in the first three quarters of 2021 is only 10.71 million yuan, which is based on a year-on-year increase of 134%. In 2020, the annual revenue of Maiwei biology is only 5.3 million yuan.
